Table 6.

List of in vivo studies in which the therapeutic potential of the administration of hMSCs for the treatment of autoimmune disorders of the lungs was evaluated.

References	Autoimmune disease	Source of hMSC	Variables	Experimental model	Clinical and laboratory effects	Mechanism proposed
(119)	Idiopathic pulmonary fibrosis	Bone marrow Umbilical cord	None	Mice	↑Survival rates ↓Pulmonary inflammation and fibrosis Effectiveness bone marrow-derived MSCs > effectiveness umbilical cord-derived MSCs	↓CD3+CD56+ NKT cells ↓CD3+CD8+ T cell induction ↑CD3+CD4+ T cells ↑CD4+CD25+CD127(low/−)/foxp3+ Tregs ↓IFN-γ ↓TNF-α ↓IL-6 ↓IL-8 ↓CCL2 ↓α-SMA activation ↑TGF-β1 ↑CXCL10
(120)	Idiopathic pulmonary fibrosis	Adipose tissue	None	Mice	↑Survival rates ↓Ashcroft's modified score for lung fibrosis ↓Lung weight ↓Lung pathology ↓Collagen deposition in the lungs	↓IL-2 ↓IL-1β ↓TNF-α ↓TGF-β ↓bFGF ↓CTGF ↓COL3a1 ↓CoL1a1 ↓Matrix metalloproteinases ↓Tissue inhibitor of metalloproteinases

Both the methodology employed and the results obtained by each article are represented in this table. α-SMA, alpha-smooth muscle actin; IL-8, interleukin 8; CTGF, connective tissue growth factor; COL3a1, collagen alpha-1(III) chain; CoL1a1, collagen, type I, alpha 1.